Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Glutathione for Prevention of Paclitaxel/Carboplatin-Induced Peripheral Neuropathy

Despite evidence supporting the potential benefit of glutathione in the prevention of chemotherapy-induced peripheral neuropathy (CIPN), results of this trial of 185 patients showed no benefit in preventing CIPN as … Continue reading

April 1, 2014

MITO-7 Focuses on Quality of Life: Weekly Carboplatin and Paclitaxel vs the Every 3-Week Standard

“Our primary study hypothesis was that the experimental weekly schedule could produce an improvement in health-related quality of life, compared with the standard schedule.” http://www.practiceupdate.com/expertopinion/833  Following the successful completion of … Continue reading

March 17, 2014

Carboplatin plus Paclitaxel Once a Week Versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multi-Centre, Open-Label, Phase 3 Trial

”A weekly regimen of carboplatin and paclitaxel might be a reasonable option for first-line treatment of women with advanced ovarian cancer.” http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970049- X/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, … Continue reading

March 17, 2014

Independent Radiologic Review Confirms Benefit of Bevacizumab with Gemcitabine and Carboplatin in Recurrent Ovarian Cancer

Independent radiologic review of the phase III OCEANS trial of gemcitabine–carboplatin with or without bevacizumab in platinum-sensitive, recurrent ovarian cancer confirmed the statistically significant increased PFS and objective response rate … Continue reading

March 3, 2014

Controversy in Treatment of Advanced Ovarian Cancer

“Although questions still remain over dosing and timing of first-line treatment for patients with advanced ovarian cancer, the JGOG study provides important data that will help guide patient care in … Continue reading

September 3, 2013

Improved Progression-free and Overall Survival: Phase III Trial

In this long-term follow-up of a phase III trial of Japanese patients with stage II–IV ovarian cancer, patients treated with weekly paclitaxel and every 3-week carboplatin had improved progression-free and … Continue reading

September 3, 2013

Current Standards of Care for Chemotherapy of Optimally Cytoreduced Advanced Epithelial Ovarian Cancer

Highlights Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer. Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in … Continue reading

June 21, 2013

Paclitaxel-Carboplatin for Platinum-Resistant Ovarian Cancer

To combat the toxicities associated with paclitaxel plus cisplatin therapy in patients with platinum-resistant epithelial ovarian cancer, researchers are experimenting with a new combination—paclitaxel plus carboplatin (Paraplatin, Bristol-Myers Squibb)—and early … Continue reading

April 16, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada